Evondos Group confirms two key leadership appointments to support European growth

Tom Ellison appointed Chief Financial Officer, while Rasmus Platz takes up role of Chief Business Development Officer as company implements strategic priorities for 2026

Evondos Group, a European health-tech provider transforming home healthcare and the market leader in automated medication dispensing, has announced the appointment of two senior executives. To support rapid growth plans, Tom Ellison will take up the role of Chief Financial Officer (CFO), while Rasmus Platz has been appointed Chief Business Development Officer (CBDO).

Ellison has led finance teams in SaaS companies across Europe, most recently serving as Global CFO of Mendix, an enterprise low-code platform leader owned by Siemens. Prior to this, he spent four years as Senior Director of Finance at ServiceNow. Ellison brings deep experience in scaling high-growth technology businesses, as well as healthcare sector experience from GE Healthcare across Europe. Ellison is a US national living in Amsterdam and replaces Vesa Tiitinen following a successful seven-year tenure as CFO of Evondos Group.

Platz has built an impressive track record in healthcare business development, most recently as Global Head of Business Development, Personal Health, at Philips. He has held leadership positions with international healthcare companies including Coloplast and Smith & Nephew, and brings board-level experience. Platz is a Danish national and is based in Copenhagen.

Ellison and Platz will report to Evondos Group Chief Executive Officer, Frans Cromme, who took the helm in August 2025. He said: “Evondos Group has a clear mission to transform home healthcare across Europe by freeing up time for healthcare professionals to deliver meaningful care. With simple, easy-to-use technology, we enable people to live at home independently for longer and improve medical outcomes.

“With an aging population and growing shortage of carers, technology must play an increasingly important role to allow people to live at home longer. Tom and Rasmus join Evondos Group on a clear path to deliver that.”

Two-pronged European growth strategy in 2026

Evondos Group is the leading provider of automated medicine dispensing services in northern Europe. By supporting healthcare professionals, the group helps focus on meaningful care work, while increasing efficiency. The company has two key areas of growth in focus:

• Evondos Group is rapidly expanding its geographical footprint in the eight European markets it currently serves, including the Netherlands following the acquisition of Medido in 2023. The company has 40,000 devices deployed with individual clients across the continent, and has dispensed more than 120 million medication sachets to date. Throughout 2026, the group is focused on strengthening its industry-leading position in the Nordics and the Netherlands, while positioning the UK as a key growth market. Further geographic expansion is expected in new EU markets through a mix of organic and inorganic growth.
• Evondos Group is broadening its portfolio to include remote patient monitoring technologies, including the deployment of Vitacam, which the group acquired in 2024. This disruptive service measures vital physiological parameters such as heartbeat, oxygen saturation and respiratory rate from a short video stream, using AI-powered computer vision techniques and remote photoplethysmography. This allows clinicians to get a more complete view of changes in health, without needing to be physically present.

About Evondos

Evondos Group is a leading European health-tech company providing automated medicine-dispensing services. It operates across eight markets in Europe. With a decade-long, proven track record of delivering independence and choice, Evondos is delivering measurable impact at scale in the care sector.

Supporting 700+ municipalities and care organisations, and more than 30,000 nurses and carers daily, the company helps more than 40,000 people to live independently.

Evondos delivers better medical outcomes for healthcare providers, pairing proven clinical performance with market-leading reliability. Its devices have dispensed over 120 million medicine sachets, saving eight million nursing days, with a 99.5% adherence rate, slowing health deterioration through dependable, compliant delivery.

For more information, please visit our website: www.evondos.com.